Amicus Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Amicus Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Amicus Therapeutics Inc Strategy Report
- Understand Amicus Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Amicus Therapeutics Inc (Amicus Therapeutics) is a biotechnology company, which focuses on the research, development and commercialization of small molecule drugs and orally administered drugs known as pharmacological chaperones for the treatment of rare and orphan diseases. It's lead product, migalastat HCl, a small molecule, is indicated for the treatment of Fabry disease. The other products in the pipeline include ATB200/AT2221 for the treatment of Pompe disease, Fabry disease, and other lysosomal storage disorders; migalastat for other conditions; and enzyme replacement therapies for other rare diseases. The company has presence in the US, the UK, Ireland, France, the Netherlands, Germany, Spain, Italy and Japan. Amicus Therapeutics is headquartered in Philadelphia, Pennsylvania, the US.
Headquarters
United States of America
Address
3675 Market Street, Philadelphia, Pennsylvania, 19104
Website
www.amicusrx.com
Telephone
1 215 9217600
No of Employees
517
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
FOLD (NASD)
Revenue (2022)
$399.4M
21.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
35.9%
(2022 vs 2021)
Market Cap*
$3.2B
Net Profit Margin (2022)
XYZ
47.2%
(2022 vs 2021)
* As of and is in US$
Amicus Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed Product: | Amicus Assist |
| Migalastat HCl - Fabry disease | CHART |
| Pipeline | Galafold |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Financing Agreements | In October, the company entered into an agreement for US$430 million financing collaboration with funds managed by Blackstone. |
| 2023 | Regulatory Approval | In September, the company secured an approval from the U.S. Food and Drug Administration for Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) 65mg capsules for adults living with late-onset Pompe disease. |
| 2023 | Contracts/Agreements | In September, the company selected Orsini Specialty Pharmacy to dispense Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat), a two-component treatment approved for certain patients with late-onset Pompe disease. |
Competitor Comparison
| Key Parameters | Amicus Therapeutics Inc | BioMarin Pharmaceutical Inc | RegeneRx Biopharmaceuticals Inc | Astellas Gene Therapies | Dewpoint Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Philadelphia | Novato | Rockville | San Francisco | Boston |
| State/Province | Pennsylvania | California | Maryland | California | Massachusetts |
| No. of Employees | 517 | 3,401 | 2 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John F. Crowley | Chairman | Executive Board | 2022 | 55 |
| Bradley L. Campbell | Director; President; Chief Executive Officer | Executive Board | 2022 | 46 |
| Simon Harford | Chief Financial Officer | Senior Management | 2023 | - |
| Samantha Prout | Chief Accounting Officer | Senior Management | 2023 | - |
| Ellen S. Rosenberg | Chief Legal Officer | Senior Management | 2019 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward